NASDAQ:GOSS Gossamer Bio Q2 2025 Earnings Report $0.17 +0.01 (+6.86%) As of 12:21 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gossamer Bio EPS ResultsActual EPS-$0.17Consensus EPS -$0.18Beat/MissBeat by +$0.01One Year Ago EPSN/AGossamer Bio Revenue ResultsActual Revenue$11.49 millionExpected Revenue$4.12 millionBeat/MissBeat by +$7.37 millionYoY Revenue GrowthN/AGossamer Bio Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time4:00PM ETUpcoming EarningsGossamer Bio's Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gossamer Bio Earnings HeadlinesGossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of "Hold" by AnalystsJune 12 at 4:31 AM | americanbankingnews.comGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 4, 2026 | finance.yahoo.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 15 at 1:00 AM | Weiss Ratings (Ad)Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 3, 2026 | businesswire.comGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 2, 2026 | finance.yahoo.comGossamer Bio Extends Early Deadline in Note ExchangeJune 2, 2026 | tipranks.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations. Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the ShowWhy Oracle's 10% Drop May Be Telling the Wrong Story Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
